← Pharma & APIs
Critical node· Pharma & APIs · Critical anchor
Catalent, fill-finish (Bloomington)
Bloomington (Indiana), United States39.15°N 86.54°W
computed criticality22/100
reading
Acquired by Novo Holdings for $16.5bn (Dec. 2024); 3 sites resold to Novo Nordisk for $11bn
2024Fault line
Catalent, a reference contract manufacturer for the sterile fill-finish of injectables, was acquired by Novo Holdings for $16.5bn (closing 18 December 2024), which immediately sold three sites, Bloomington, Brussels, Anagni, to Novo Nordisk for $11bn. The Bloomington site had accumulated five FDA observations (Form 483) in November 2023, including the presence of pests on a sterile line. The deal removes a neutral third-party capacity from the market for the exclusive benefit of Novo's GLP-1s, tightening the fill-finish bottleneck.
Actors
Novo Holdings (Copenhagen)
Novo Nordisk (Bagsværd)
Catalent (Somerset, NJ)
Depends on 4
Borosilicate glass, Schott (Mainz)Pharma & APIs · Critical anchor↗WuXi Biologics, WuxiPharma & APIs · Critical anchor↗Samsung Biologics, SongdoPharma & APIs · Link↗Novo Nordisk, Kalundborg (Denmark)Pharma & APIs · Critical anchor↗Feeds 1
Drug shortages, FDA / EMA / WHOPharma & APIs↗Sources